Why This Study Matters
Head and neck squamous cell carcinoma (HNSCC) accounts for approximately 946 000 new cases and 482 000 deaths annually worldwide, according to the paper's introduction. For locally advanced (stage III to IVB) disease, 5-year overall survival ranges from 25% to 60% in contemporary cohorts despite multimodal treatment, and intensive treatment often impairs function and quality of life.
Immune checkpoint inhibitors already help in recurrent or metastatic HNSCC, and the phase 3 KEYNOTE-689 trial showed improved EFS with perioperative pembrolizumab. The best way to weave immunotherapy through the neoadjuvant, surgical and adjuvant phases is still undefined. CAMORAL tested the anti–PD-1 antibody camrelizumab combined with chemotherapy before surgery, followed by adjuvant camrelizumab.
Study Design
CAMORAL was a multicenter, open-label, phase 2 randomized clinical trial run at 4 academic hospitals in China (Shanghai, Guangzhou, Jinan and Wuhan) between October 2020 and March 2024, with a data cutoff of April 11, 2025. Patients were randomized 1:1 using stratified block randomization (stratified by ECOG performance status, 0 vs 1, and tumor stage, III vs IV). No masking was applied.
125 patients randomized (63 vs 62) at 4 academic hospitals, 1:1 and open-label, with a median follow-up of 24.6 months (IQR, 16.8-36.5).
| Arm | Treatment |
|---|---|
| Neoadjuvant-adjuvant (n = 63) | Two 21-day cycles of albumin-bound paclitaxel (100 mg/m² days 1, 8, 15), carboplatin (AUC 5, day 1) or cisplatin (75 mg/m², day 1), and camrelizumab 200 mg (day 1); surgery 3 to 6 weeks later; risk-adapted adjuvant therapy; adjuvant camrelizumab 200 mg every 3 weeks for up to 15 cycles |
| Control (n = 62) | Upfront surgery followed by standard risk-adapted adjuvant therapy |
Primary end point: 2-year EFS. Secondary end points included MPR, pCR, OS, distant metastasis–free survival (DMFS), locoregional recurrence–free survival (LRFS) and safety. The sample-size calculation assumed 2-year EFS of 63% (control) vs 83% (experimental), requiring 39 events and a planned sample of approximately 123 participants.
Patient Population
Eligible patients were aged 18 to 75 years with previously untreated, resectable stage III to IVB HNSCC (nasopharyngeal carcinoma excluded), ECOG performance status 0 to 1, and no prior PD-1/PD-L1 inhibitor exposure. Of 125 participants, 99 (79.2%) were male and mean (SD) age was 56.3 (11.7) years; 103 (82.4%) had oral cavity primary tumors.
| Characteristic | Neoadjuvant-adjuvant (n = 63) | Control (n = 62) |
|---|---|---|
| Mean (SD) age, y | 54.2 (10.6) | 58.4 (12.5) |
| Age ≥65 y | 9 (14.3%) | 23 (37.1%) |
| Male | 46 (73.0%) | 53 (85.5%) |
| Stage IV | 49 (77.8%) | 47 (75.8%) |
| Oral cavity primary | 50 (79.4%) | 53 (85.5%) |
| PD-L1 CPS ≥20 | 24 (38.1%) | 17 (27.4%) |
| HPV positive | 3 (4.8%) | 2 (3.2%) |
PD-L1 CPS ≥20 was more frequent in the neoadjuvant-adjuvant group, and CPS was not a stratification factor.
Primary Endpoint Results
In the intention-to-treat population, 13 EFS events (20.6%) occurred in the neoadjuvant-adjuvant group versus 29 (46.8%) in the control group. The 2-year EFS rate was 77.8% (95% CI, 63.6-87.0) versus 46.1% (95% CI, 31.3-59.6) (stratified HR, 0.34; 95% CI, 0.17-0.68; P = .001). Median EFS was not reached with the combination and was 21.5 months (95% CI, 8.6 months to not estimable) in the control group.
| Outcome | Neoadjuvant-adjuvant | Control | Effect |
|---|---|---|---|
| 2-year EFS | 77.8% (63.6-87.0) | 46.1% (31.3-59.6) | HR 0.34 (0.17-0.68); P = .001 |
| MPR | 30 (47.6%; 34.9-60.6) | 0 | nominal P < .001 |
| pCR | 16 (25.4%; 15.3-37.9) | 0 | nominal P < .001 |
| 2-year OS | 92.0% (81.8-96.6) | 69.1% (54.5-79.8) | HR 0.25 (0.10-0.64); nominal P = .002 |
| DMFS | — | — | HR 0.15 (0.03-0.68); nominal P = .005 |
| LRFS | — | — | HR 0.61 (0.28-1.30); P = .20 |
Among the 13 EFS events in the combination group, 12 were locoregional progression or recurrence and 1 was a distant metastasis. The control group had 13 locoregional events, 10 distant metastases, 2 deaths and 4 second primary malignant neoplasms. 5-year outcomes were not yet mature and are not reported.
Subgroup Analyses
The authors report that prespecified subgroup analyses showed consistent EFS benefit across most subgroups, including age, tumor stage, PD-L1 expression and primary tumor site, with a similar favorable OS trend. They label these analyses exploratory and caution that PD-L1 results should be interpreted carefully given the baseline CPS imbalance. Subgroup-level hazard ratios appear only in the supplement (eFigures) and are not reproduced in the main text, so no subgroup statistics are given here.
| Subgroup | Hazard ratio / CI / P |
|---|---|
| Age, tumor stage, PD-L1 expression, primary site | Not specified in source (main text); qualitative statement only |
Safety Profile
Treatment-emergent adverse events (TEAEs) of any grade occurred in 63 (100%) vs 61 (98.4%) patients. Grade 3 or higher TEAEs were more common with the combination (50 of 63 [79.4%] vs 35 of 62 [56.5%]). Serious AEs occurred in 17 (27.0%) vs 12 (19.4%). One fatal TEAE occurred in the control group and none in the combination group. TEAEs led to permanent discontinuation of camrelizumab in 11 participants (17.5%). Adherence to the adjuvant phase was incomplete: all 63 were assigned adjuvant camrelizumab, but 42 (66.7%) received at least 1 cycle and 16 (25.4%) completed more than 10 cycles. Surgical delays occurred in 10 of 58 operated patients (17.2%) in the combination group, mainly COVID-19–related (n = 7), and none in the control group.
| Event | Combo any grade | Combo grade ≥3 | Control any grade | Control grade ≥3 |
|---|---|---|---|---|
| Any TEAE | 63 (100) | 50 (79.4) | 61 (98.4) | 35 (56.5) |
| Lymphopenia | 54 (85.7) | 29 (46.0) | 48 (77.4) | 14 (22.6) |
| Neutropenia | 46 (73.0) | 17 (27.0) | 4 (6.5) | 0 |
| Oral mucositis | 35 (55.6) | 15 (23.8) | 44 (71.0) | 16 (25.8) |
| Leukopenia | 55 (87.3) | 9 (14.3) | 16 (25.8) | 1 (1.6) |
| Anemia | 57 (90.5) | 7 (11.1) | 44 (71.0) | 2 (3.2) |
| Reactive cutaneous capillary endothelial proliferation | 57 (90.5) | 0 | 0 | 0 |
Values are No. (%). The table lists a selection of common events from the paper's Table 2 (events in at least 20% of either group).
Interpretation and Broader Context
In conclusion, the CAMORAL trial provides robust preliminary evidence that perioperative camrelizumab plus chemotherapy significantly improves EFS and pathological responses in resectable locally advanced HNSCC without compromising surgical outcomes or introducing unmanageable toxic effects.
— Liu et al., JAMA Oncology, Conclusions
The authors frame the result as a signal supporting an adequately powered phase 3 trial, not as a basis for changing practice. The trial did not compare chemoimmunotherapy with perioperative PD-1 blockade alone, so the added value of chemotherapy is uncertain.
Both CAMORAL and KEYNOTE-689 showed improved DMFS without a significant LRFS difference, which the authors read as benefit driven by control of distant micrometastases. The authors compared their results with KEYNOTE-689 (2-year EFS 77.8% vs 65.0% for the experimental arms; control arms 46.1% vs 54.6%), but stress that cross-trial comparisons require caution because the populations differ (all-Chinese cohort, 85.5% oral cavity primaries in CAMORAL vs 60.7% in KEYNOTE-689). The KEYNOTE-689 figures are a cross-trial benchmark, not a result from this trial.
Limitations
Limitations noted by the authors: modest sample size; median follow-up of 24.6 months; baseline PD-L1 CPS ≥20 imbalance; biomarker analysis limited to PD-L1; and no direct comparison with perioperative PD-1 blockade alone.
Also worth noting: the trial was open-label, and per the funding statement Jiangsu Hengrui Pharmaceuticals Co, Ltd had a role in the design of the study, data collection, analysis and interpretation, and manuscript preparation; one author reported employment by the company. Funding: Shanghai's Top Priority Research Center; Clinical Study Program of Shanghai Ninth People's Hospital; nonfinancial support from Jiangsu Hengrui Pharmaceuticals Co, Ltd.